Zevra Therapeutics Outperforms Salarius Pharmaceuticals in Key Metrics

Zevra Therapeutics (NASDAQ: ZVRA) has emerged as a more favorable investment compared to Salarius Pharmaceuticals (NASDAQ: SLRX), based on a comprehensive analysis of their respective financial and operational metrics. This assessment encompasses factors such as analyst recommendations, profitability, institutional ownership, and risk profiles, revealing significant insights for potential investors.

Comparative Analyst Ratings and Price Targets

Recent data from MarketBeat.com shows that Zevra Therapeutics commands a consensus price target of $22.80, representing a potential upside of 161.02%. In contrast, Salarius Pharmaceuticals has not garnered similar enthusiasm from analysts, indicating that Zevra is perceived as the stronger investment option. The higher consensus rating and substantial upside potential suggest that equity research analysts favor Zevra Therapeutics significantly over Salarius Pharmaceuticals.

Profitability, Earnings, and Valuation Insights

A closer examination of profitability reveals that while Salarius Pharmaceuticals boasts higher earnings, it generates lower revenue compared to Zevra Therapeutics. Furthermore, Salarius is currently trading at a more attractive price-to-earnings ratio, suggesting it may be the more affordable choice among the two stocks. This aspect could appeal to value-conscious investors looking for potential growth without excessive spending.

Institutional ownership plays a vital role in assessing the confidence of large investors in these companies. Approximately 35.0% of Zevra Therapeutics shares are held by institutional investors, compared to just 11.9% for Salarius Pharmaceuticals. Additionally, insider ownership is significant, with 2.4% of Zevra’s shares owned by insiders versus a mere 0.3% for Salarius. Such figures often indicate that larger financial entities and insiders expect the stock to outperform the market over time.

Volatility is another critical factor in investment decisions. Zevra Therapeutics has a beta of 1.01, suggesting its stock price is slightly more volatile than the S&P 500. In contrast, Salarius Pharmaceuticals presents a much lower beta of 0.4, indicating its stock price is 60% less volatile than the broader market. This lower volatility may appeal to risk-averse investors.

In summary, Zevra Therapeutics outperforms Salarius Pharmaceuticals in 12 out of the 13 evaluated factors, positioning it as a more compelling investment opportunity.

About Zevra Therapeutics

Zevra Therapeutics, Inc. specializes in discovering and developing proprietary prodrugs aimed at treating serious medical conditions in the United States. The company operates its products through the Ligand Activated Therapy platform. Its lead candidate, KP1077, is currently undergoing Phase 2 clinical trials for treating idiopathic hypersomnia, while another variant, KP1077N, is in Phase 1/2 trials for narcolepsy treatment.

Additionally, Zevra is developing Celiprolol, a prodrug in Phase 1/2 trials for vascular Ehlers Danlos syndrome. The company’s portfolio includes AZSTARYS, a once-daily ADHD treatment for children aged six years and older, OLPRUVA for urea cycle disorders, and Arimoclomol, which targets Niemann-Pick disease type C, a rare neurodegenerative condition. Zevra also maintains collaboration agreements with various organizations to enhance the development and commercialization of its product candidates. Formerly known as KemPharm, Inc., the company rebranded to Zevra Therapeutics, Inc. in February 2023 and is headquartered in Celebration, Florida.

About Salarius Pharmaceuticals

Salarius Pharmaceuticals, Inc. is a clinical-stage biotechnology firm focused on developing innovative treatments for cancers with unmet medical needs. Its lead candidate, Seclidemstat (SP-2577), is a small molecular inhibitor currently in Phase I/II clinical trials targeting advanced solid tumors and Ewing sarcoma. The company is also advancing SP-3164, a small molecular protein degrader for hematological and solid tumors.

Salarius has forged a strategic partnership with the University of Utah Research Foundation, securing exclusive licensing rights for patent protections related to SP-2577 and its associated compounds. Based in Houston, Texas, Salarius Pharmaceuticals continues to explore avenues for product development and commercialization as it seeks to address critical healthcare challenges.

As the market evolves, the comparative strengths of these two biotechnology firms highlight the importance of thorough analysis and informed decision-making for potential investors.